×
DaVita Receivables 2010-2024 | DVA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
DaVita receivables for the quarter ending September 30, 2024 were
$2.631B
, a
10.66% increase
year-over-year.
DaVita receivables for 2023 were
$2.416B
, a
5.28% decline
from 2022.
DaVita receivables for 2022 were
$2.551B
, a
5.81% increase
from 2021.
DaVita receivables for 2021 were
$2.411B
, a
1.16% decline
from 2020.
View More
DaVita Receivables 2010-2024 | DVA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
DaVita receivables for 2023 were
$2.416B
, a
5.28% decline
from 2022.
DaVita receivables for 2022 were
$2.551B
, a
5.81% increase
from 2021.
DaVita receivables for 2021 were
$2.411B
, a
1.16% decline
from 2020.
Related Stocks
Company Name
Market
Cap
Fresenius SE (FSNUY)
$19.5B
Quest Diagnostics (DGX)
$18B
Encompass Health (EHC)
$10B
Chemed (CHE)
$8.2B
Elanco Animal Health (ELAN)
$6.6B
RadNet (RDNT)
$5.9B
Option Care Health (OPCH)
$3.7B
Amedisys (AMED)
$2.9B
LifeStance Health (LFST)
$2.8B
Astrana Health (ASTH)
$2.3B
Addus HomeCare (ADUS)
$2.2B
U.S Physical Therapy (USPH)
$1.4B
Aveanna Healthcare Holdings (AVAH)
$1.1B
Pennant (PNTG)
$1.1B
Atai Life Sciences (ATAI)
$290M
Daxor (DXR)
$43M
MEDIROM Healthcare Technologies (MRM)
$15M
Psychemedics (PMD)
$14M
ATI Physical Therapy (ATIP)
$8M
Ontrak (OTRK)
$8M
IMAC Holdings (BACK)
$1M